Quizartinib was evaluated in a multicenter, randomized phase 3 study investigating the type 2 FLT3i quizartinib (60 mg daily) versus salvage chemotherapy in patients with R/R FLT3-ITD-mutated AML with a prior remission duration of 6 months or less [26]. Here, FLT3 is linked to acute myeloid leukemia.